Which has stronger valuation and earnings, NTRA or NUVL?

Natera has higher revenue and earnings than Nuvalent. Natera is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.50B 18.12 -$208.16M -$1.63 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is NTRA or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to Natera's net margin of -9.05%. Natera's return on equity of -14.74% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Natera -9.05% -14.74% -10.27% Nuvalent N/A -40.11% -35.43%

Which has stronger earnings & valuation, BIIB or NUVL?

Biogen has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.08 $1.29B $5.65 36.53 Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is BIIB or NUVL more profitable?

Biogen has a net margin of 8.32% compared to Nuvalent's net margin of 0.00%. Biogen's return on equity of 11.18% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Nuvalent N/A -40.11% -35.43%

Is NUVL or ROIV more profitable?

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Roivant Sciences -3,629.19% -20.54% -19.43%

Which has higher earnings and valuation, INCY or NUVL?

Incyte has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.75 $1.29B $7.85 15.35 Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is INCY or NUVL more profitable?

Incyte has a net margin of 27.71% compared to Nuvalent's net margin of 0.00%. Incyte's return on equity of 29.93% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Nuvalent N/A -40.11% -35.43%

Nuvalent (NUVL) Competitors

$123.96 0.00 (0.00%)

As of 07/16/2026

Compare

NUVL vs. NTRA, BIIB, ALNY, ROIV, and INCY

Should you buy Nuvalent stock or one of its competitors? MarketBeat compares Nuvalent with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvalent include Natera (NTRA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), and Incyte (INCY). These companies are all part of the "biotechnology" industry.

How does Nuvalent compare to Natera?

Natera (NASDAQ:NTRA) and Nuvalent (NASDAQ:NUVL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Natera has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Natera has higher revenue and earnings than Nuvalent. Natera is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.50B	18.12	-$208.16M	-$1.63	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent has a net margin of 0.00% compared to Natera's net margin of -9.05%. Natera's return on equity of -14.74% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-9.05%	-14.74%	-10.27%
Nuvalent	N/A	-40.11%	-35.43%

Natera presently has a consensus target price of $296.74, suggesting a potential downside of 6.24%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

In the previous week, Natera had 35 more articles in the media than Nuvalent. MarketBeat recorded 35 mentions for Natera and 0 mentions for Nuvalent. Natera's average media sentiment score of 0.83 beat Nuvalent's score of 0.00 indicating that Natera is being referred to more favorably in the media.

Company	Overall Sentiment
Natera	Positive
Nuvalent	Neutral

99.9% of Natera shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Natera beats Nuvalent on 13 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Biogen?

Biogen (NASDAQ:BIIB) and Nuvalent (NASDAQ:NUVL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Biogen had 30 more articles in the media than Nuvalent. MarketBeat recorded 30 mentions for Biogen and 0 mentions for Nuvalent. Biogen's average media sentiment score of 0.97 beat Nuvalent's score of 0.00 indicating that Biogen is being referred to more favorably in the media.

Company	Overall Sentiment
Biogen	Positive
Nuvalent	Neutral

Biogen presently has a consensus price target of $224.61, suggesting a potential upside of 8.83%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given Biogen's stronger consensus rating and higher possible upside, equities analysts clearly believe Biogen is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Biogen has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.08	$1.29B	$5.65	36.53
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

87.9% of Biogen shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Biogen has a net margin of 8.32% compared to Nuvalent's net margin of 0.00%. Biogen's return on equity of 11.18% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Nuvalent	N/A	-40.11%	-35.43%

Summary

Biogen beats Nuvalent on 13 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Nuvalent (NASDAQ:NUVL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Alnylam Pharmaceuticals had 44 more articles in the media than Nuvalent. MarketBeat recorded 44 mentions for Alnylam Pharmaceuticals and 0 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.00 beat Alnylam Pharmaceuticals' score of -0.08 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Overall Sentiment
Alnylam Pharmaceuticals	Neutral
Nuvalent	Neutral

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alnylam Pharmaceuticals presently has a consensus price target of $396.72, suggesting a potential upside of 83.11%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Nuvalent's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Nuvalent	N/A	-40.11%	-35.43%

Alnylam Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.81	$313.75M	$5.38	40.27
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Alnylam Pharmaceuticals beats Nuvalent on 12 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Roivant Sciences?

Nuvalent (NASDAQ:NUVL) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvalent currently has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Roivant Sciences has a consensus target price of $34.77, suggesting a potential downside of 3.67%. Given Nuvalent's higher probable upside, research analysts clearly believe Nuvalent is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Roivant Sciences had 20 more articles in the media than Nuvalent. MarketBeat recorded 20 mentions for Roivant Sciences and 0 mentions for Nuvalent. Roivant Sciences' average media sentiment score of 1.17 beat Nuvalent's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvalent	Neutral
Roivant Sciences	Positive

Roivant Sciences has higher revenue and earnings than Nuvalent. Roivant Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Roivant Sciences	$8.26M	3,143.45	-$299.77M	-$0.60	N/A

Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Roivant Sciences beats Nuvalent on 11 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Incyte?

Incyte (NASDAQ:INCY) and Nuvalent (NASDAQ:NUVL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

97.0% of Incyte shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Incyte had 23 more articles in the media than Nuvalent. MarketBeat recorded 23 mentions for Incyte and 0 mentions for Nuvalent. Incyte's average media sentiment score of 0.85 beat Nuvalent's score of 0.00 indicating that Incyte is being referred to more favorably in the media.

Company	Overall Sentiment
Incyte	Positive
Nuvalent	Neutral

Incyte has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.75	$1.29B	$7.85	15.35
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Incyte has a net margin of 27.71% compared to Nuvalent's net margin of 0.00%. Incyte's return on equity of 29.93% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Nuvalent	N/A	-40.11%	-35.43%

Incyte currently has a consensus price target of $120.40, suggesting a potential downside of 0.05%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

Incyte beats Nuvalent on 12 of the 15 factors compared between the two stocks.

Get Nuvalent News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVL vs. The Competition

Export

Metric	Nuvalent	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.79B	$3.64B	$6.97B	$12.96B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-20.46	8.39	270.81	25.99
Price / Sales	N/A	1,273.00	663.27	110.95
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	7.77	18.01	13.19	6.23
Net Income	-$425.38M	-$13.22M	$3.45B	$342.69M
7 Day Performance	N/A	5.39%	4.15%	4.15%
1 Month Performance	0.15%	-4.07%	-2.00%	-1.18%
1 Year Performance	71.78%	57.33%	76.52%	22.08%

Nuvalent Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVL Nuvalent	1.7152 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
NTRA Natera	2.975 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+92.1%	$38.35B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up
BIIB Biogen	3.9852 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+59.5%	$29.99B	$9.89B	35.72	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.7718 of 5 stars	$220.33 +7.2%	$402.67 +82.8%	-49.5%	$27.50B	$3.71B	40.95	2,770	Trending News Analyst Forecast Analyst Revision
ROIV Roivant Sciences	1.64 of 5 stars	$33.32 -1.7%	$33.59 +0.8%	+201.3%	$24.39B	$8.26M	N/A	860	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUVL) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvalent (NUVL) Competitors